1
|
Golder S, Klein A, O'Connor K, Wang Y, Gonzalez‐Hernandez G. Social Media Posts on Statins: What Can We Learn About Patient Experiences and Perspectives? J Am Heart Assoc 2024; 13:e033992. [PMID: 38533982 PMCID: PMC11179751 DOI: 10.1161/jaha.124.033992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 02/02/2024] [Indexed: 03/28/2024]
Affiliation(s)
- Su Golder
- University of YorkYorkUnited Kingdom
| | - Ari Klein
- University of PennsylvaniaPhiladelphiaPAUSA
| | | | - Yunwen Wang
- Cedars Sinai Medical CenterWest HollywoodCAUSA
| | | |
Collapse
|
2
|
Rochoy M, Danel A, Chazard E, Gautier S, Berkhout C. Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions. Therapie 2022; 77:683-691. [PMID: 35660259 DOI: 10.1016/j.therap.2022.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 02/02/2022] [Accepted: 03/14/2022] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Some users of anabolic androgenic steroids (AAS) secretly consume aromatase inhibitors (AI) and selective oestrogen receptor modulators (SERM). Cyber-forums can be potential sources of information. Our aim was to determine the cycles used, and to identify the adverse drug reactions (ADRs) experienced, reported in a bodybuilding forum. METHOD We collected discussions on a French forum for AAS users (MESO-Rx®), from January 2013 to 2019 on concerning clomiphene, tamoxifen, anastrozole, exemestane and letrozole were collected. Characteristics of the users, duration of cures, treatments, dosages, point of purchase and occurrence of ADRs were analysed. RESULTS Among the 1792 posts published on the forum, 845 concerned SERM and 571 concerned AI, i.e. 2180 drugs used (several cycles included concomitant consumption). Our population was exclusively male, with an average age of 28.2±6.3years, and had been practising weight training for 6.7±5.6years. The SERMs were mainly used to "revive the hypothalamohypophyseal axis" and the AIs to "fight against androgen aromatisation". The median treatment duration was 22 days for SERM, 70days for anastrozole, 84days for exemestane and 30days for letrozole, with a mean dose of 69mg/d for clomiphene, 22mg/d for tamoxifen, 0.4mg/d for anastrozole, 10mg/d for exemestane, 2mg/d for letrozole. The main way of obtaining these drugs was through the internet. 157 ADRs were identified: 95 for SERMs and 62 for AI. The most represented were acne, musculoskeletal, mood and reproductive disorders. Impaired quality of life (according to the patient) was described in 54% of the SERM posts and 26% of the AI posts. CONCLUSIONS Patient narratives posted on forums can be a useful tool in the context of doping, to better understand practices, motivations and possibly to bring up pharmacovigilance signals.
Collapse
Affiliation(s)
- Michaël Rochoy
- General Practice Department, University Lille, 59000 Lille, France; Public Health Department, University Lille, CHU de Lille, ULR 2694, CERIM, 59000 Lille, France; University Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, UMR-S1172, Degenerative and Vascular Cognitive Disorders, 59045 Lille, France.
| | - Antoine Danel
- General Practice Department, University Lille, 59000 Lille, France
| | - Emmanuel Chazard
- Public Health Department, University Lille, CHU de Lille, ULR 2694, CERIM, 59000 Lille, France
| | - Sophie Gautier
- University Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, UMR-S1172, Degenerative and Vascular Cognitive Disorders, 59045 Lille, France
| | - Christophe Berkhout
- General Practice Department, University Lille, 59000 Lille, France; Department of primary and interprofessional care, University of Antwerp, 2000 Antwerp, Belgium
| |
Collapse
|
3
|
Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project. Drug Saf 2020; 43:835-851. [PMID: 32557179 DOI: 10.1007/s40264-020-00951-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The large-scale use of social media by the population has gained the attention of stakeholders and researchers in various fields. In the domain of pharmacovigilance, this new resource was initially considered as an opportunity to overcome underreporting and monitor the safety of drugs in real time in close connection with patients. Research is still required to overcome technical challenges related to data extraction, annotation, and filtering, and there is not yet a clear consensus concerning the systematic exploration and use of social media in pharmacovigilance. Although the literature has mainly considered signal detection, the potential value of social media to support other pharmacovigilance activities should also be explored. The objective of this paper is to present the main findings and subsequent recommendations from the French research project Vigi4Med, which evaluated the use of social media, mainly web forums, for pharmacovigilance activities. This project included an analysis of the existing literature, which contributed to the recommendations presented herein. The recommendations are categorized into three categories: ethical (related to privacy, confidentiality, and follow-up), qualitative (related to the quality of the information), and quantitative (related to statistical analysis). We argue that the progress in information technology and the societal need to consider patients' experiences should motivate future research on social media surveillance for the reinforcement of classical pharmacovigilance.
Collapse
|
4
|
Gras-Champel V, Masmoudi I, Batteux B, Merle PE, Liabeuf S, Masmoudi K. Statin-associated myasthenia: A case report and literature review. Therapie 2020; 75:301-309. [DOI: 10.1016/j.therap.2019.07.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 05/06/2019] [Accepted: 07/10/2019] [Indexed: 12/01/2022]
|
5
|
Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. INTERNATIONAL JOURNAL OF DATA SCIENCE AND ANALYTICS 2019. [DOI: 10.1007/s41060-019-00175-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
6
|
Lardon J, Bellet F, Aboukhamis R, Asfari H, Souvignet J, Jaulent MC, Beyens MN, Lillo-LeLouët A, Bousquet C. Evaluating Twitter as a complementary data source for pharmacovigilance. Expert Opin Drug Saf 2018; 17:763-774. [DOI: 10.1080/14740338.2018.1499724] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Jérémy Lardon
- Sorbonne Université, UPMC Université Paris 06, UMR_S 1142, LIMICS, Paris, France
- INSERM, U1142, LIMICS, Paris, France
- Université Paris 13, Sorbonne Paris Cité, LIMICS (UMR_S 1142), Bobigny, France
- Department of Public Health and medical informatics, CHU University of Saint-Etienne, Saint-Etienne, France
| | - Florelle Bellet
- Centre de Pharmacovigilance, Centre Hospitalier Universitaire (CHU) University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Rim Aboukhamis
- Centre Régional de Pharmacovigilance, Hôpital Européen Georges Pompidou – Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Hadyl Asfari
- Sorbonne Université, UPMC Université Paris 06, UMR_S 1142, LIMICS, Paris, France
- INSERM, U1142, LIMICS, Paris, France
| | - Julien Souvignet
- Sorbonne Université, UPMC Université Paris 06, UMR_S 1142, LIMICS, Paris, France
- INSERM, U1142, LIMICS, Paris, France
- Université Paris 13, Sorbonne Paris Cité, LIMICS (UMR_S 1142), Bobigny, France
- Department of Public Health and medical informatics, CHU University of Saint-Etienne, Saint-Etienne, France
| | - Marie-Christine Jaulent
- Sorbonne Université, UPMC Université Paris 06, UMR_S 1142, LIMICS, Paris, France
- INSERM, U1142, LIMICS, Paris, France
- Université Paris 13, Sorbonne Paris Cité, LIMICS (UMR_S 1142), Bobigny, France
| | - Marie-Noëlle Beyens
- Centre de Pharmacovigilance, Centre Hospitalier Universitaire (CHU) University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Agnès Lillo-LeLouët
- Centre Régional de Pharmacovigilance, Hôpital Européen Georges Pompidou – Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Cédric Bousquet
- Sorbonne Université, UPMC Université Paris 06, UMR_S 1142, LIMICS, Paris, France
- INSERM, U1142, LIMICS, Paris, France
- Université Paris 13, Sorbonne Paris Cité, LIMICS (UMR_S 1142), Bobigny, France
- Department of Public Health and medical informatics, CHU University of Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
7
|
Karapetiantz P, Bellet F, Audeh B, Lardon J, Leprovost D, Aboukhamis R, Morlane-Hondère F, Grouin C, Burgun A, Katsahian S, Jaulent MC, Beyens MN, Lillo-Le Louët A, Bousquet C. Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions. Front Pharmacol 2018; 9:439. [PMID: 29765326 PMCID: PMC5938397 DOI: 10.3389/fphar.2018.00439] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 04/13/2018] [Indexed: 01/28/2023] Open
Abstract
Background: Social media have drawn attention for their potential use in Pharmacovigilance. Recent work showed that it is possible to extract information concerning adverse drug reactions (ADRs) from posts in social media. The main objective of the Vigi4MED project was to evaluate the relevance and quality of the information shared by patients on web forums about drug safety and its potential utility for pharmacovigilance. Methods: After selecting websites of interest, we manually evaluated the relevance of the content of posts for pharmacovigilance related to six drugs (agomelatine, baclofen, duloxetine, exenatide, strontium ranelate, and tetrazepam). We compared forums to the French Pharmacovigilance Database (FPVD) to (1) evaluate whether they contained relevant information to characterize a pharmacovigilance case report (patient’s age and sex; treatment indication, dose and duration; time-to-onset (TTO) and outcome of the ADR, and drug dechallenge and rechallenge) and (2) perform impact analysis (nature, seriousness, unexpectedness, and outcome of the ADR). Results: The cases in the FPVD were significantly more informative than posts in forums for patient description (age, sex), treatment description (dose, duration, TTO), and outcome of the ADR, but the indication for the treatment was more often found in forums. Cases were more often serious in the FPVD than in forums (46% vs. 4%), but forums more often contained an unexpected ADR than the FPVD (24% vs. 17%). Moreover, 197 unexpected ADRs identified in forums were absent from the FPVD and the distribution of the MedDRA System Organ Classes (SOCs) was different between the two data sources. Discussion: This study is the first to evaluate if patients’ posts may qualify as potential and informative case reports that should be stored in a pharmacovigilance database in the same way as case reports submitted by health professionals. The posts were less informative (except for the indication) and focused on less serious ADRs than the FPVD cases, but more unexpected ADRs were presented in forums than in the FPVD and their SOCs were different. Thus, web forums should be considered as a secondary, but complementary source for pharmacovigilance.
Collapse
Affiliation(s)
- Pierre Karapetiantz
- Sorbonne Université, INSERM, Université Paris 13, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Paris, France
| | - Florelle Bellet
- Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France
| | - Bissan Audeh
- Université de Lyon, IMT Mines Saint-Etienne, Institut Henri Fayol, Département ISI, Université Jean Monnet, Institut d'Optique Graduate School, Centre National de la Recherche Scientifique, Laboratoire Hubert Curien, Saint-Étienne, France
| | - Jérémy Lardon
- Sorbonne Université, INSERM, Université Paris 13, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Paris, France
| | - Damien Leprovost
- Sorbonne Université, INSERM, Université Paris 13, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Paris, France
| | - Rim Aboukhamis
- Centre Régional de Pharmacovigilance, Hôpital Européen Georges-Pompidou, Assistance Publique - Hôpitaux de Paris, Paris, France
| | | | - Cyril Grouin
- LIMSI, CNRS, Université Paris-Saclay, Orsay, France
| | - Anita Burgun
- INSERM UMRS1138 Centre de Recherche des Cordeliers, Paris, France.,Département d'Informatique Médicale, Hôpital Européen Georges-Pompidou, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Sandrine Katsahian
- INSERM UMRS1138 Centre de Recherche des Cordeliers, Paris, France.,Département d'Informatique Médicale, Hôpital Européen Georges-Pompidou, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Marie-Christine Jaulent
- Sorbonne Université, INSERM, Université Paris 13, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Paris, France
| | - Marie-Noëlle Beyens
- Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France
| | - Agnès Lillo-Le Louët
- Centre Régional de Pharmacovigilance, Hôpital Européen Georges-Pompidou, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Cédric Bousquet
- Sorbonne Université, INSERM, Université Paris 13, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Paris, France
| |
Collapse
|